Anti-CASP9 (CLEAVED-ASP353), C-Terminal antibody produced in rabbit

Name	Anti-CASP9 (CLEAVED-ASP353), C-Terminal antibody produced in rabbit
Supplier	Sigma-Aldrich
Catalog	SAB4502569
Prices	$335.50
Sizes	100 µg
Host	Rabbit
Clonality	Polyclonal
Applications	IHC WB
Species Reactivities	Mouse, Rat
Antigen	Synthesized peptide derived from human CSPN9 (CLEAVED-ASP353)
Description	Rabbit Polyclonal
Gene	Casp9
Conjugate	unconjugated
Supplier Page	Shop

Product images

<B>Immunohistochemistry</B><BR/>Anti-CSPN9 (CLEAVED-ASP<SUP>353</SUP>): <B>Cat. No. SAB4502569</B>: Immunohistochemistry analysis of paraffin-embedded human lung carcinoma tissue using Anti-CSPN9 (CLEAVED-ASP<SUP>353</SUP>) antibody. Cells on the left were treated with the Anti-CSPN9 (CLEAVED-ASP<SUP>353</SUP>) antibody. Cells on the right (negative control) were treated with both Anti-CSPN9 (CLEAVED-ASP<SUP>353</SUP>) antibody and the synthesized immunogen peptide.

Immunohistochemistry
Anti-CSPN9 (CLEAVED-ASP³⁵³): Cat. No. SAB4502569: Immunohistochemistry analysis of paraffin-embedded human lung carcinoma tissue using Anti-CSPN9 (CLEAVED-ASP³⁵³) antibody. Cells on the left were treated with the Anti-CSPN9 (CLEAVED-ASP³⁵³) antibody. Cells on the right (negative control) were treated with both Anti-CSPN9 (CLEAVED-ASP³⁵³) antibody and the synthesized immunogen peptide.

<B>Immunoblotting</B><BR/>Anti-CSPN9 (CLEAVED-ASP<SUP>353</SUP>): <B>Cat. No. SAB4502569</B>: Immunoblotting analysis of extracts from NIH-3T3 cells, treated with Etoposide 25uM 60′, using Anti-CSPN9 (CLEAVED-ASP<SUP>353</SUP>) antibody. The lane on the left was treated with the Anti-CSPN9 (CLEAVED-ASP<SUP>353</SUP>) antibody. The lane on the right (negative control) was treated with both Anti-CSPN9 (CLEAVED-ASP<SUP>353</SUP>) antibody and the synthesized immunogen peptide.

Immunoblotting
Anti-CSPN9 (CLEAVED-ASP³⁵³): Cat. No. SAB4502569: Immunoblotting analysis of extracts from NIH-3T3 cells, treated with Etoposide 25uM 60′, using Anti-CSPN9 (CLEAVED-ASP³⁵³) antibody. The lane on the left was treated with the Anti-CSPN9 (CLEAVED-ASP³⁵³) antibody. The lane on the right (negative control) was treated with both Anti-CSPN9 (CLEAVED-ASP³⁵³) antibody and the synthesized immunogen peptide.